Compare Heron Therapeutics Inc (HRTX) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Tapestry, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while Tapestry, Inc. trades at $116.27 (market cap $23.09B). The key difference: Tapestry, Inc. is far larger — about 339.5× Heron Therapeutics Inc's market cap, and Tapestry, Inc. pays a 1.6% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Tapestry, Inc. for 70 Days on average.
| HRTX | TPR | |
|---|---|---|
Market Cap | $68.01M | $23.09B |
Volume | 1,891,941 | 2,745,259 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $164.78 |
52-Week Low | $0.27 | $98.81 |
Typical Hold Time | 35 Days | 70 Days |
Enterprise Value | $174.75M | $25.89B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
TPR trades at $116.24, up 2.51% today, showing strong momentum after recent earnings beats. The stock faces technical resistance near $117-119 but maintains bullish analyst support with a $174.64 consensus target. Recent financials show revenue growth to $7.01B in 2025, though net income declined to $183M. The company benefits from strong brand performance with Coach driving growth, while expanding digital presence through Google partnerships.
Outlook remains positive with 73% analyst buy ratings and projected 2026 revenue of $8B. Key risks include Kate Spade execution challenges, tariff pressures, and premium valuation at 15.93 P/E. The stock offers 50% upside to consensus target but requires monitoring of margin expansion and international growth execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
